Table 2.
Aerobic training-responsive transcriptome gene changes: high vs. low responders (P < 0.05)
| Affymetrix ProbeSet | Gene Symbol | Gene Title | High Responders | Low Responders |
|---|---|---|---|---|
| 211980_at | COL4A1 | Collagen, type IV, alpha 1 | 5.8 ± 0.79† | 3.1 ± 0.29 |
| 228915_at | DACH1 | Dachshund homolog 1 (Drosophila) | 5.3 ± 0.96† | 1.8 ± 0.46 |
| 225681_at | CTHRC1 | Collagen triple helix repeat containing 1 | 4.7 ± 0.78 | 2.8 ± 0.51 |
| 204114_at | NID2 | Nidogen 2 (osteonidogen) | 3.6 ± 0.37* | 2.3 ± 0.26 |
| 211966_at | COL4A2 | Collagen, type IV, alpha 2 | 3.5 ± 0.66* | 1.9 ± 0.08 |
| 226140_s_at | OTUD1 | OTU domain containing 1 | 3.4 ± 1.07* | −1.1 ± 0.23 |
| 200665_s_at | SPARC | Secreted protein, acidic, cysteine-rich (osteonectin) | 3.1 ± 0.40 | 2.2 ± 0.23 |
| 1558214_s_at | CTNNA1 | Catenin (cadherin-associated protein), alpha 1, 102 kDa | 3.0 ± 0.58 | 1.5 ± 0.45 |
| 202202_s_at | LAMA4 | Laminin, alpha 4 | 2.9 ± 0.36* | 1.9 ± 0.12 |
| 205047_s_at | ASNS | Asparagine synthetase | 2.7 ± 0.60* | 1.2 ± 0.18 |
| 230061_at | TM4SF18 | Transmembrane 4 L six family member 18 | 2.7 ± 0.34* | 1.7 ± 0.20 |
| 213139_at | SNAI2 | Snail homolog 2 (Drosophila) | 2.6 ± 0.44* | 1.6 ± 0.14 |
| 202409_at | IGF2 −3′UTR | Insulin-like growth factor 2 (somatomedin A) | 2.5 ± 0.22* | 1.9 ± 0.18 |
| 215277_at | PCDH1 | Protocadherin 1 | 2.5 ± 0.60 | 1.2 ± 0.22 |
| 227415_at | LOC283508 | Hypothetical protein LOC283508 | 2.5 ± 0.37* | 1.4 ± 0.12 |
| 224833_at | ETS1 | v-ets erythroblastosis virus E26 oncogene Homolog 1 (avian) | 2.5 ± 0.38* | 1.4 ± 0.10 |
| 202878_s_at | CD93 | CD93 molecule | 2.4 ± 0.31* | 1.6 ± 0.09 |
| 214660_at | PELO | Pelota homolog (Drosophila) | 2.4 ± 0.24* | 1.5 ± 0.23 |
| 203934_at | KDR | Kinase insert domain receptor (a type III receptor tyrosine kinase) | 2.4 ± 0.32* | 1.5 ± 0.21 |
| 212365_at | MYO1B | Myosin IB | 2.4 ± 0.48* | 1.3 ± 0.12 |
| 233025_at | PDZD2 | PDZ domain containing 2 | 2.4 ± 0.53* | 1.1 ± 0.15 |
| 204821_at | BTN3A3 | Butyrophilin, subfamily 3, member A3 | 2.4 ± 0.55* | 1.1 ± 0.19 |
| 225056_at | SIPA1L2 | Signal-induced proliferation-associated 1 like 2 | 2.4 ± 0.39* | 1.3 ± 0.27 |
| 244840_x_at | DOCK4 | Dedicator of cytokinesis 4 | 2.4 ± 0.49* | −1.1 ± 0.13 |
| 213592_at | APLNR | Apelin receptor | 2.3 ± 0.25 | 1.7 ± 0.22 |
| 202270_at | GBP1 | Guanylate binding protein 1, interferon-inducible, 67 kDa | 2.3 ± 0.29* | 1.4 ± 0.21 |
| 1557286_at | 1557286_at | 2.2 ± 0.44* | 1.1 ± 0.19 | |
| 204115_at | GNG11 | Guanine nucleotide binding protein (G protein), gamma 11 | 2.2 ± 0.17* | 1.7 ± 0.13 |
| 202008_s_at | NID1 | Nidogen 1 | 2.2 ± 0.22* | 1.6 ± 0.16 |
| 1554233_at | C1QTNF9 | C1q and tumor necrosis factor related protein 9 | 2.2 ± 0.32* | 1.2 ± 0.13 |
| 212298_at | NRP1 | Neuropilin 1 | 2.2 ± 0.19* | 1.4 ± 0.19 |
| 203324_s_at | CAV2 | Caveolin 2 | 2.1 ± 0.26* | 1.5 ± 0.13 |
| 236335_at | 236335_at | 2.1 ± 0.20* | 1.5 ± 0.12 | |
| 210105_s_at | FYN | FYN oncogene related to SRC, FGR, YES | 2.1 ± 0.19† | 1.4 ± 0.12 |
| 1553530_a_at | ITGB1 | Integrin, beta 1 | 2.1 ± 0.31* | 1.3 ± 0.11 |
| 217979_at | TSPAN13 | Tetraspanin 13 | 2.1 ± 0.19* | 1.4 ± 0.14 |
| 201655_s_at | HSPG2 | Heparan sulfate proteoglycan 2 | 2.1 ± 0.25 | 1.5 ± 0.07 |
| 210029_at | IDO1 | Indoleamine 2,3-dioxygenase 1 | 2.1 ± 0.25* | 1.4 ± 0.15 |
| 237026_at | 237026_at | 2.1 ± 0.35* | 1.1 ± 0.24 | |
| 1555812_a_at | ARHGDIB | Rho GDP dissociation inhibitor (GDI) beta | 2.1 ± 0.21* | 1.4 ± 0.08 |
| 215034_s_at | TM4SF1 | Transmembrane 4 L six family member 1 | 2.0 ± 0.14* | 1.6 ± 0.15 |
| 229127_at | 229127_at | 2.0 ± 0.22* | 1.3 ± 0.16 | |
| 201215_at | PLS3 | Plastin 3 (T isoform) | 2.0 ± 0.21* | 1.4 ± 0.11 |
| 227443_at | C9orf150 | Chromosome 9 open reading frame 150 | 2.0 ± 0.21† | 1.3 ± 0.09 |
| 213627_at | MAGED2 | Melanoma antigen family D, 2 | 2.0 ± 0.28* | 1.1 ± 0.12 |
| 1566472_s_at | RETSAT | Retinol saturase (all-trans-retinol 13,14-reductase) | 2.0 ± 0.45 | 1.0 ± 0.14 |
| 216438_s_at | TMSB4X/TMSL3 | Thymosin b30eta 4, X-linked /// thymosin-like 3 | 2.0 ± 0.14* | 1.4 ± 0.15 |
| 238025_at | MLKL | Mixed lineage kinase domain-like | 2.0 ± 0.31* | 1.1 ± 0.13 |
| 239849_at | 239849_at | 1.9 ± 0.16† | 1.3 ± 0.11 | |
| 212097_at | CAV1 | Caveolin 1, caveolae protein, 22 kDa | 1.9 ± 0.14† | 1.4 ± 0.10 |
| 202619_s_at | PLOD2 | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | 1.9 ± 0.41* | −1.1 ± 0.06 |
| 209790_s_at | CASP6 | Caspase 6, apoptosis-related cysteine peptidase | 1.9 ± 0.50 | −1.1 ± 0.13 |
| 201753_s_at | ADD3 | Adducin 3 (gamma) | 1.9 ± 0.19* | 1.3 ± 0.17 |
| 206201_s_at | MEOX2 | Mesenchyme homeobox 2 | 1.9 ± 0.11* | 1.5 ± 0.10 |
| 205619_s_at | MEOX1 | Mesenchyme homeobox 1 | 1.9 ± 0.22* | 1.3 ± 0.14 |
| 204683_at | ICAM2 | Intercellular adhesion molecule 2 | 1.9 ± 0.20* | 1.3 ± 0.09 |
| 201399_s_at | TRAM1 | Translocation associated membrane protein 1 | 1.9 ± 0.16* | 1.3 ± 0.15 |
| 212372_at | MYH10 | Myosin, heavy chain 10, nonmuscle | 1.8 ± 0.17* | 1.3 ± 0.10 |
| 204331_s_at | MRPS12 | Mitochondrial ribosomal protein S12 | 1.8 ± 0.14* | 1.4 ± 0.13 |
| 206332_s_at | IFI16 | Interferon, gamma-inducible protein 16 | 1.8 ± 0.15* | 1.4 ± 0.10 |
| 202345_s_at | FABP5 | Fatty acid binding protein 5 (psoriasis-associated) | 1.8 ± 0.11* | 1.4 ± 0.14 |
| 226022_at | SASH1 | SAM and SH3 domain containing 1 | 1.8 ± 0.22 | 1.3 ± 0.11 |
| 201315_x_at | IFITM2 | Interferon induced transmembrane protein 2 (1-8D) | 1.7 ± 0.11† | 1.3 ± 0.10 |
| 201669_s_at | MARCKS | Myristoylated alanine-rich protein kinase C substrate | 1.7 ± 0.10† | 1.3 ± 0.06 |
| 38671_at | PLXND1 | Plexin D1 | 1.7 ± 0.16 | 1.3 ± 0.10 |
| 217757_at | A2M | Alpha-2-macroglobulin | 1.7 ± 0.09* | 1.4 ± 0.07 |
| 210762_s_at | DLC1 | Deleted in liver cancer 1 | 1.7 ± 0.17* | 1.2 ± 0.06 |
| 1558015_s_at | ACTR2 | ARP2 actin-related protein 2 homolog (yeast) | 1.7 ± 0.23* | 1.1 ± 0.11 |
| 238852_at | 238852_at | 1.7 ± 0.29* | −1.1 ± 0.13 | |
| 201776_s_at | KIAA0494 | KIAA0494 | 1.6 ± 0.12* | 1.3 ± 0.09 |
| 241929_at | CD36 | CD36 | 1.6 ± 0.11† | 1.2 ± 0.06 |
| 213932_x_at | HLA-A | Major histocompatibility complex, class I, A | 1.6 ± 0.11 | 1.3 ± 0.13 |
| 213415_at | CLIC2 | Chloride intracellular channel 2 | 1.6 ± 0.09* | 1.2 ± 0.14 |
| 208836_at | ATP1B3 | ATPase, Na+/K+ transporting, beta 3 polypeptide | 1.6 ± 0.16* | 1.1 ± 0.04 |
| 211911_x_at | HLA-B | Major histocompatibility complex, class I, B | 1.6 ± 0.08† | 1.2 ± 0.05 |
| 209543_s_at | CD34 | CD34 molecule | 1.5 ± 0.12† | 1.1 ± 0.08 |
| 218711_s_at | SDPR | Serum deprivation response (phosphatidylserine binding protein) | 1.5 ± 0.14† | −1.1 ± 0.13 |
| 214091_s_at | GPX3 | Glutathione peroxidase 3 (plasma) | 1.5 ± 0.14 | 1.2 ± 0.06 |
| 200884_at | CKB | Creatine kinase, brain | 1.5 ± 0.07* | 1.3 ± 0.07 |
| 212607_at | AKT3 | v-Akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) | 1.5 ± 0.14* | 1.1 ± 0.10 |
| 211799_x_at | HLA-C | Major histocompatibility complex, class I, C | 1.5 ± 0.07* | 1.3 ± 0.09 |
| 211006_s_at | KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | 1.5 ± 0.18† | −1.2 ± 0.10 |
| 217294_s_at | ENO1 | Enolase 1, (alpha) | 1.5 ± 0.14 | 1.1 ± 0.10 |
| 211529_x_at | HLA-G | Major histocompatibility complex, class I, G | 1.4 ± 0.07* | 1.2 ± 0.06 |
| 235371_at | GLT8D4 | Glycosyltransferase 8 domain containing 4 | 1.3 ± 0.15* | 1.9 ± 0.21 |
| 204036_at | LPAR1 | Lysophosphatidic acid receptor 1 | 1.1 ± 0.08* | 1.8 ± 0.26 |
| 217623_at | MYLK3 | Myosin light chain kinase 3 | −1.5 ± 0.05 | −1.1 ± 0.12 |
| 235309_at | RPS15A | Ribosomal protein S15a | −1.5 ± 0.05* | −1.3 ± 0.03 |
| 231792_at | MYLK2 | Myosin light chain kinase 2 | −1.6 ± 0.05* | −1.2 ± 0.05 |
| 203824_at | TSPAN8 | Tetraspanin 8 | −1.7 ± 0.07* | −1.1 ± 0.12 |
| 227577_at | EXOC8 | Exocyst complex component 8 | −1.8 ± 0.06* | −1.3 ± 0.06 |
| 238625_at | C1orf168 | Chromosome 1 open reading frame 168 | −3.9 ± 0.09* | −1.3 ± 0.17 |
Data are presented as mean fold change ± SE. Differentially expressed genes in the human high and low responders. Approximately 100 genes affected by 6 wk of aerobic exercise training were observed to be differentially expressed in human muscle of high responders when compared with low responders.
*
P < 0.05;
†
P < 0.01 for the difference between low and high responders; all remaining genes, P < 0.07.